Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Pfizer
Kyowa Kirin Co., Ltd.
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Prothena Biosciences Ltd.
University of Iowa
Baylor College of Medicine
Fenwal, Inc.